Hyde opens European office

By Nick Taylor

- Last updated on GMT

Hyde Engineering + Consulting has opened an office in Dublin, Ireland, enhancing its ability to provide Europe-based biopharm with compliance, qualification and automation services.

The office is Hyde’s first in Europe, complementing existing sites in the US, India, China, Malaysia and Singapore. Establishing a presence in Europe is intended to improve Hyde’s ability to provide local expertise to existing clients, such as Pfizer and Lonza, and gain new business.

With our European expansion we can now work more closely with facility manufacturers, providing new paradigms for engineering design and operations for compliance​”, explained Simon Forder, CEO of Hyde.

Speaking to in-PharmaTechnologist Will Czerniak, director, European operations at Hyde, added that the company has done business in the region since 1994 and now felt like the right time to expand.

Hyde has experienced an increase in projects in Europe, said Czerniak, and is optimistic that operations will grow in coming years. This is expected to lead to growth and expansion of the company’s services and staff.

Ireland was selected as the office location because of the talent and manufacturing capacity it provides for Hyde’s clients.

Savings in the downturn

Czerniak added that there has been “a dearth of large projects​” during the economic downturn but smaller, more niche work has ensured “Hydeis busier than ever​” and was well ahead of its targets in recent financials.

Forder explained that the economic situation facing biopharm companies means they increasingly “require greater efficiencies and significant reduction in the cost of goods​”.

Hyde believes its services can help achieve these savings. The company’s offering spans process design and engineering, planning and project management, clean-in-place (CIP) and sterilisation-in-place (SIP), compliance engineering and training programmes.

Czerniak added that Hyde has experienced an upturn in projects and spending, giving the company reason to be optimistic that business is growing again.

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers